Acute pain (less than 3 months in duration)
Previous serious adverse event or hypersensitivity to cannabis or cannabinoids
Inability to understand and comply with the instructions of the study
Presence of significant cardiac disease (history of unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension) that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction
Current substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)
Life-time history of dependence on cannabis or diagnosis of cannabis use disorder (CUD) according to the DSM 5
Life-time history of DSM 5 schizophrenia, bipolar disorder, or previous psychosis with or intolerance to cannabinoids
Current or history of suicidal ideation
Pregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception
Hepatic impairment (aspartate aminotransferase more than three times normal) or renal function impairment (serum creatinine level >133 µmol/L, Estimated Glomerular Filtration Rate (eGFR) <60)
Cognitive impairment according to MiniCog
The patient is currently using or has used cannabinoid based medications within 90 days of study entry and is unwilling to abstain for the duration of the study
Positive urine drug screen for cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)
Participation in another clinical trial within 30 days of enrolment in our trial

NCT03337503_exc_T1
Condition
pain
NCT03337503_exc_T2
Measurement
duration
NCT03337503_exc_T3
Value
less than 3 months
NCT03337503_exc_T4
Qualifier
Acute
NCT03337503_exc_T5
Scope
less than 3 months in duration
NCT03337503_exc_T6
Condition
hypersensitivity
NCT03337503_exc_T7
Drug
cannabis
NCT03337503_exc_T8
Drug
cannabinoids
NCT03337503_exc_T9
Scope
cannabis or cannabinoids
NCT03337503_exc_T10
Condition
adverse event
NCT03337503_exc_T11
Qualifier
serious
NCT03337503_exc_T13
Condition
cardiac disease
NCT03337503_exc_T14
Qualifier
significant
NCT03337503_exc_T15
Condition
unstable ischemic heart disease
NCT03337503_exc_T16
Condition
heart failure
NCT03337503_exc_T17
Qualifier
severe
NCT03337503_exc_T18
Qualifier
uncontrolled
NCT03337503_exc_T19
Condition
hypertension
NCT03337503_exc_T20
Observation
history
NCT03337503_exc_T21
Scope
unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension
NCT03337503_exc_T22
Qualifier
clinically significant
NCT03337503_exc_T23
Condition
arrhythmia
NCT03337503_exc_T24
Condition
myocardial infarction
NCT03337503_exc_T25
Scope
arrhythmia or myocardial infarction
NCT03337503_exc_T26
Mood
at risk of
NCT03337503_exc_T27
Scope
significant cardiac disease
NCT03337503_exc_T28
Condition
substance use disorder
NCT03337503_exc_T29
Qualifier
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)
NCT03337503_exc_T30
Condition
dependence on cannabis
NCT03337503_exc_T31
Condition
cannabis use disorder (CUD)
NCT03337503_exc_T32
Qualifier
DSM 5
NCT03337503_exc_T33
Qualifier
DSM 5
NCT03337503_exc_T34
Condition
schizophrenia
NCT03337503_exc_T35
Condition
bipolar disorder
NCT03337503_exc_T36
Condition
psychosis
NCT03337503_exc_T37
Condition
intolerance
NCT03337503_exc_T38
Drug
cannabinoids
NCT03337503_exc_T39
Condition
suicidal ideation
NCT03337503_exc_T40
Temporal
Current
NCT03337503_exc_T41
Observation
history
NCT03337503_exc_T42
Scope
Current or history
NCT03337503_exc_T44
Condition
Hepatic impairment
NCT03337503_exc_T45
Measurement
Estimated Glomerular Filtration Rate (eGFR)
NCT03337503_exc_T46
Value
<60
NCT03337503_exc_T47
Measurement
aspartate aminotransferase
NCT03337503_exc_T48
Value
more than three times normal
NCT03337503_exc_T49
Condition
renal function impairment
NCT03337503_exc_T50
Measurement
serum creatinine level
NCT03337503_exc_T51
Value
>133 µmol/L
NCT03337503_exc_T52
Scope
serum creatinine level >133 µmol/L, Estimated Glomerular Filtration Rate (eGFR) <60
NCT03337503_exc_T53
Condition
Cognitive impairment
NCT03337503_exc_T54
Procedure
MiniCog
NCT03337503_exc_T55
Drug
cannabinoid based medications
NCT03337503_exc_T56
Temporal
within 90 days of study entry
NCT03337503_exc_T57
Measurement
urine drug screen
NCT03337503_exc_T58
Value
Positive
NCT03337503_exc_T59
Drug
cannabinoids
NCT03337503_exc_T60
Drug
alcohol
NCT03337503_exc_T61
Drug
cocaine
NCT03337503_exc_T62
Drug
amphetamines
NCT03337503_exc_T63
Drug
methamphetamines
NCT03337503_exc_T64
Drug
opioids
NCT03337503_exc_T65
Qualifier
unprescribed
NCT03337503_exc_T66
Scope
cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)